Implant placement guide

Description

FIG. 1 is a perspective view of our design for an implant placement guide.

FIG. 2 is a first side view of the design for the implant placement guide of FIG. 1;

FIG. 3 is a second side view of the design for the implant placement guide of FIG. 1;

FIG. 4 is a front view of the design for the implant placement guide of FIG. 1;

FIG. 5 is a back view of the design for the implant placement guide of FIG. 1;

FIG. 6 is a top view for the design for the implant placement guide of FIG. 1; and,

FIG. 7 is a bottom view for the design of the implant placement guide of FIG. 1.

The broken lines shown are included for the purpose of illustrating portions of the implant placement guide that form no part of the claim.

Claims

The ornamental design for an implant placement guide, as shown and described.

US Referenced Citations (860)

Number	Name	Date	Kind
1655158	Muir	Jan 1928	A
2110208	Eggert	Mar 1938	A
2168437	Buercklin	Aug 1939	A
2531724	Cevasco	Nov 1950	A
2643653	Heidrich	Jun 1953	A
D179537	Floyd	Jan 1957	S
3016895	Sein	Jan 1962	A
3025991	Gillon	Mar 1962	A
3122162	Sands	Feb 1964	A
3523906	Vrancken et al.	Aug 1970	A
3538916	Groff et al.	Nov 1970	A
3620216	Szymanski	Nov 1971	A
3625214	Higuchi	Dec 1971	A
3632768	Bergy et al.	Jan 1972	A
3669104	Wyatt et al.	Jun 1972	A
3691090	Kitajima et al.	Sep 1972	A
D226915	Huggins	May 1973	S
3732865	Higuchi et al.	May 1973	A
3737337	Schnoring et al.	Jun 1973	A
3766915	Rychlik	Oct 1973	A
3773919	Boswell et al.	Nov 1973	A
3797492	Place	Mar 1974	A
3869549	Geller	Mar 1975	A
3891570	Fukushima et al.	Jun 1975	A
D236035	Ciencewicki	Jul 1975	S
3960757	Morishita et al.	Jun 1976	A
3987790	Eckenhoff et al.	Oct 1976	A
3995631	Higuchi et al.	Dec 1976	A
3995632	Nakano et al.	Dec 1976	A
4008719	Theeuwes et al.	Feb 1977	A
4034756	Higuchi et al.	Jul 1977	A
4078060	Benson et al.	Mar 1978	A
4105030	Kercso	Aug 1978	A
4111201	Theeuwes	Sep 1978	A
4111202	Theeuwes	Sep 1978	A
4111203	Theeuwes	Sep 1978	A
4203439	Theeuwes	May 1980	A
4211771	Witkowski et al.	Jul 1980	A
4221862	Naito et al.	Sep 1980	A
4223674	Fluent et al.	Sep 1980	A
4243030	Lynch et al.	Jan 1981	A
D258837	Spranger et al.	Apr 1981	S
D259458	Fuller	Jun 1981	S
4305927	Theeuwes et al.	Dec 1981	A
4310516	Chang et al.	Jan 1982	A
4340054	Michaels	Jul 1982	A
4350271	Eckenhoff	Sep 1982	A
4373527	Fischell	Feb 1983	A
4376118	Daher et al.	Mar 1983	A
4384975	Fong	May 1983	A
4389330	Tice et al.	Jun 1983	A
D271990	Lyne	Dec 1983	S
4439196	Higuchi	Mar 1984	A
4444498	Heinemann	Apr 1984	A
4451253	Harman	May 1984	A
4455143	Theeuwes et al.	Jun 1984	A
4455145	Theeuwes	Jun 1984	A
4474572	McNaughton et al.	Oct 1984	A
4530840	Tice et al.	Jul 1985	A
4552561	Eckenhoff et al.	Nov 1985	A
4588614	Lauchenauer	May 1986	A
4594108	Greminger, Jr. et al.	Jun 1986	A
4597753	Turley	Jul 1986	A
4609374	Ayer	Sep 1986	A
4639244	Rizk et al.	Jan 1987	A
4655462	Balsells	Apr 1987	A
4673405	Guittard et al.	Jun 1987	A
4675184	Hasegawa et al.	Jun 1987	A
4695623	Stabinsky	Sep 1987	A
4727138	Goeddel et al.	Feb 1988	A
4734284	Terada et al.	Mar 1988	A
4737437	Gutsell, Jr. et al.	Apr 1988	A
4743449	Yoshida et al.	May 1988	A
4753651	Eckenhoff	Jun 1988	A
4762791	Goeddel et al.	Aug 1988	A
4765989	Wong et al.	Aug 1988	A
4783337	Wong et al.	Nov 1988	A
4818517	Kwee et al.	Apr 1989	A
4820267	Harman	Apr 1989	A
4820638	Swetly et al.	Apr 1989	A
4826144	Balsells	May 1989	A
4830344	Balsells	May 1989	A
4834708	Pillari	May 1989	A
4840896	Reddy et al.	Jun 1989	A
4845196	Cowling	Jul 1989	A
4847079	Kwan	Jul 1989	A
4851228	Zentner et al.	Jul 1989	A
4865845	Eckenhoff et al.	Sep 1989	A
4871094	Gall et al.	Oct 1989	A
4873080	Brickl et al.	Oct 1989	A
4874388	Wong et al.	Oct 1989	A
4876781	Balsells	Oct 1989	A
4882166	Graham et al.	Nov 1989	A
4885166	Meyer et al.	Dec 1989	A
4886668	Haslam et al.	Dec 1989	A
4892778	Theeuwes et al.	Jan 1990	A
4893795	Balsells	Jan 1990	A
4897471	Stabinsky	Jan 1990	A
4907788	Balsells	Mar 1990	A
4915366	Balsells	Apr 1990	A
4915949	Wong et al.	Apr 1990	A
4915954	Ayer et al.	Apr 1990	A
4917887	Hauptmann et al.	Apr 1990	A
4917895	Lee et al.	Apr 1990	A
4923805	Reddy et al.	May 1990	A
4927687	Nuwayser	May 1990	A
4929554	Goeddel et al.	May 1990	A
4931285	Edgren et al.	Jun 1990	A
4934666	Balsells	Jun 1990	A
4940465	Theeuwes et al.	Jul 1990	A
4940588	Sparks et al.	Jul 1990	A
4952402	Sparks et al.	Aug 1990	A
4957119	de Nijs	Sep 1990	A
4961253	Balsells	Oct 1990	A
4964204	Balsells	Oct 1990	A
4969884	Yum	Nov 1990	A
4974821	Balsells	Dec 1990	A
4976966	Theeuwes et al.	Dec 1990	A
4994028	Leonard et al.	Feb 1991	A
5004689	Fiers et al.	Apr 1991	A
5006346	Theeuwes et al.	Apr 1991	A
5019382	Cummins, Jr.	May 1991	A
5019400	Gombotz et al.	May 1991	A
5023088	Wong et al.	Jun 1991	A
5024842	Edgren et al.	Jun 1991	A
5030216	Theeuwes et al.	Jul 1991	A
5034229	Magruder et al.	Jul 1991	A
5053014	Van Heugten	Oct 1991	A
5057318	Magruder et al.	Oct 1991	A
5059423	Magruder et al.	Oct 1991	A
5066436	Komen et al.	Nov 1991	A
5071642	Lahr et al.	Dec 1991	A
5072070	Balsells	Dec 1991	A
5079388	Balsells	Jan 1992	A
5090962	Landry et al.	Feb 1992	A
5091188	Haynes	Feb 1992	A
5108078	Balsells	Apr 1992	A
5110596	Magruder et al.	May 1992	A
5112614	Magruder et al.	May 1992	A
5113938	Clayton	May 1992	A
5117066	Balsells	May 1992	A
D326718	Maxwell	Jun 1992	S
5118666	Habener	Jun 1992	A
5120306	Gosselin	Jun 1992	A
5120712	Habener	Jun 1992	A
5120832	Goeddel et al.	Jun 1992	A
5122128	Cardinal et al.	Jun 1992	A
5122377	Miller	Jun 1992	A
5126142	Ayer et al.	Jun 1992	A
5126147	Silvestri et al.	Jun 1992	A
5134244	Balsells	Jul 1992	A
5137727	Eckenhoff	Aug 1992	A
D329278	Gallup	Sep 1992	S
5147295	Stewart	Sep 1992	A
5151093	Theeuwes et al.	Sep 1992	A
5160122	Balsells	Nov 1992	A
5160743	Edgren et al.	Nov 1992	A
5161806	Balsells	Nov 1992	A
5180591	Margruder et al.	Jan 1993	A
5190765	Jao et al.	Mar 1993	A
5192273	Bierman	Mar 1993	A
5203849	Balsells	Apr 1993	A
5204108	Illum	Apr 1993	A
5207752	Sorensen et al.	May 1993	A
5209746	Balaban et al.	May 1993	A
5213809	Wright et al.	May 1993	A
5213810	Steber	May 1993	A
5219572	Sivaramakrishnan	Jun 1993	A
5221278	Linkwitz et al.	Jun 1993	A
5223265	Wong	Jun 1993	A
5225205	Orsolini	Jul 1993	A
5231176	Goeddel et al.	Jul 1993	A
5234424	Yum et al.	Aug 1993	A
5234692	Magruder et al.	Aug 1993	A
5234693	Magruder et al.	Aug 1993	A
5234695	Hobbs et al.	Aug 1993	A
5250026	Ehrlich et al.	Oct 1993	A
5252338	Jao et al.	Oct 1993	A
5260069	Chen	Nov 1993	A
D342855	Butler, II	Jan 1994	S
5276926	Lopez	Jan 1994	A
5278151	Korb et al.	Jan 1994	A
5279544	Gross et al.	Jan 1994	A
5279554	Turley	Jan 1994	A
5279555	Lifshey	Jan 1994	A
5279608	Cherif Cheikh	Jan 1994	A
5284655	Bogdansky et al.	Feb 1994	A
5288501	Nürnberg et al.	Feb 1994	A
5288502	Mcginity et al.	Feb 1994	A
5290271	Jemberg	Mar 1994	A
5300079	Niezink et al.	Apr 1994	A
5300302	Tachon et al.	Apr 1994	A
5308348	Balaban et al.	May 1994	A
5312335	McKinnon et al.	May 1994	A
5312389	Theeuwes et al.	May 1994	A
5312390	Wong	May 1994	A
5318558	Linkwitz et al.	Jun 1994	A
5318780	Viegas et al.	Jun 1994	A
5320616	Magndu et al.	Jun 1994	A
5324280	Wong et al.	Jun 1994	A
5336057	Fukuda et al.	Aug 1994	A
5336505	Ng et al.	Aug 1994	A
5348544	Sweeney et al.	Sep 1994	A
5352662	Brooks et al.	Oct 1994	A
5368588	Bettinger	Nov 1994	A
5368863	Eckenhoff et al.	Nov 1994	A
5371089	Rattan	Dec 1994	A
5374620	Clark et al.	Dec 1994	A
5385738	Yamahira et al.	Jan 1995	A
5385887	Yim et al.	Jan 1995	A
5395319	Hirsch et al.	Mar 1995	A
5407609	Tice et al.	Apr 1995	A
D358644	Park	May 1995	S
5411951	Mitchell	May 1995	A
5413572	Wong et al.	May 1995	A
5413672	Hirotsuji et al.	May 1995	A
5424286	Eng	Jun 1995	A
5428024	Chu et al.	Jun 1995	A
5429602	Hauser	Jul 1995	A
5439688	Orson et al.	Aug 1995	A
5443459	Wong et al.	Aug 1995	A
5445829	Paradissis et al.	Aug 1995	A
5456679	Balaban et al.	Oct 1995	A
5458888	Chen	Oct 1995	A
5464929	Bezwada et al.	Nov 1995	A
5472708	Chen	Dec 1995	A
5478564	Wantier et al.	Dec 1995	A
5484403	Yoakum et al.	Jan 1996	A
5486365	Takado et al.	Jan 1996	A
5498255	Wong et al.	Mar 1996	A
5511355	Dingler	Apr 1996	A
5512293	Landrau et al.	Apr 1996	A
5512549	Chen et al.	Apr 1996	A
5514110	Teh	May 1996	A
5529914	Hubbell et al.	Jun 1996	A
5531736	Wong et al.	Jul 1996	A
5540665	Mercado et al.	Jul 1996	A
5540912	Roorda et al.	Jul 1996	A
5541172	Labrie et al.	Jul 1996	A
5542682	Goldstein et al.	Aug 1996	A
5543156	Roorda et al.	Aug 1996	A
5545618	Buckley et al.	Aug 1996	A
5556642	Kobayashi et al.	Sep 1996	A
5557318	Gabriel	Sep 1996	A
5558637	Allonen et al.	Sep 1996	A
5569289	Yoon	Oct 1996	A
5571525	Roorda et al.	Nov 1996	A
5574008	Johnson et al.	Nov 1996	A
5574137	Gray et al.	Nov 1996	A
5580578	Oshlack et al.	Dec 1996	A
5589167	Cleland et al.	Dec 1996	A
5595751	Bezwada	Jan 1997	A
5595759	Wright et al.	Jan 1997	A
5597579	Bezwada et al.	Jan 1997	A
5602010	Hauptmann et al.	Feb 1997	A
5605688	Himmler et al.	Feb 1997	A
5607687	Bezwada et al.	Mar 1997	A
5609885	Rivera et al.	Mar 1997	A
5613954	Nelson et al.	Mar 1997	A
5614221	Fjellstrom	Mar 1997	A
5614492	Habener	Mar 1997	A
5618552	Bezwada et al.	Apr 1997	A
5620698	Bezwada et al.	Apr 1997	A
5620705	Dong et al.	Apr 1997	A
5630796	Bellhouse et al.	May 1997	A
5633011	Dong et al.	May 1997	A
5635213	Nystrom et al.	Jun 1997	A
5639477	Maruyama et al.	Jun 1997	A
5639640	Reddy et al.	Jun 1997	A
5645850	Bezwada et al.	Jul 1997	A
5648088	Bezwada et al.	Jul 1997	A
5650173	Ramstack et al.	Jul 1997	A
5654008	Herbert et al.	Aug 1997	A
5654010	Johnson et al.	Aug 1997	A
5656297	Bernstein et al.	Aug 1997	A
5656299	Kino et al.	Aug 1997	A
5658593	Orly et al.	Aug 1997	A
5660847	Magruder et al.	Aug 1997	A
5660858	Parikh et al.	Aug 1997	A
5660861	Jao et al.	Aug 1997	A
5667808	Johnson et al.	Sep 1997	A
5668170	Gyory	Sep 1997	A
5672549	Minami et al.	Sep 1997	A
5676942	Testa et al.	Oct 1997	A
5686097	Taskovich et al.	Nov 1997	A
5688801	Mesens et al.	Nov 1997	A
5690925	Gray et al.	Nov 1997	A
5690952	Magruder et al.	Nov 1997	A
5695463	Cherif-Cheikh	Dec 1997	A
5697113	Shatz	Dec 1997	A
5697914	Brimhall	Dec 1997	A
5698213	Jamiolkowski et al.	Dec 1997	A
5700486	Canal et al.	Dec 1997	A
5700583	Jamiolkowski et al.	Dec 1997	A
5703200	Bezwada et al.	Dec 1997	A
5707644	Illum	Jan 1998	A
5711967	Juch	Jan 1998	A
5713847	Howard, III et al.	Feb 1998	A
5718922	Herrero-Vanrell	Feb 1998	A
5725497	Woodruff et al.	Mar 1998	A
5728088	Margruder et al.	Mar 1998	A
5728396	Peery et al.	Mar 1998	A
5733572	Unger et al.	Mar 1998	A
5736159	Chen et al.	Apr 1998	A
5738845	Imakawa	Apr 1998	A
5747058	Tipton et al.	May 1998	A
5756450	Lorenz et al.	May 1998	A
5767251	Reddy et al.	Jun 1998	A
5770231	Mesens et al.	Jun 1998	A
5782396	Mastri et al.	Jul 1998	A
5792477	Rickey et al.	Aug 1998	A
5795591	Lee et al.	Aug 1998	A
5795779	McCormick et al.	Aug 1998	A
5807876	Armistead et al.	Sep 1998	A
5810769	Schlegel et al.	Sep 1998	A
5814323	Lyle	Sep 1998	A
D399821	Tyneski	Oct 1998	S
5817129	Labrecque et al.	Oct 1998	A
5827297	Boudjema	Oct 1998	A
5830501	Dong et al.	Nov 1998	A
5836935	Ashton et al.	Nov 1998	A
5843891	Sherman	Dec 1998	A
5844017	Jamiolkowski et al.	Dec 1998	A
5851451	Takechi et al.	Dec 1998	A
5858746	Hubbell et al.	Jan 1999	A
5859150	Jamiolkowski et al.	Jan 1999	A
5861166	Eckenhoff	Jan 1999	A
5871770	Margruder et al.	Feb 1999	A
5871778	Kino et al.	Feb 1999	A
5874388	Hsu	Feb 1999	A
5876746	Jona et al.	Mar 1999	A
5882676	Lee et al.	Mar 1999	A
D408917	Hacker	Apr 1999	S
5904935	Eckenhoff et al.	May 1999	A
5906599	Kaldany	May 1999	A
5906816	Soos et al.	May 1999	A
5906830	Farinas et al.	May 1999	A
5908621	Glue et al.	Jun 1999	A
5916598	Rickey et al.	Jun 1999	A
5922253	Herbert et al.	Jul 1999	A
5928666	Farinas et al.	Jul 1999	A
5932547	Stevenson et al.	Aug 1999	A
5938654	Wong et al.	Aug 1999	A
5939286	Johnson et al.	Aug 1999	A
5942223	Bazer et al.	Aug 1999	A
5942253	Gombotz et al.	Aug 1999	A
5945126	Thanoo et al.	Aug 1999	A
5948430	Zerbe et al.	Sep 1999	A
5951521	Mastrototaro et al.	Sep 1999	A
5958909	Habener	Sep 1999	A
D415073	Meehan	Oct 1999	S
5962023	Jamiolkowski et al.	Oct 1999	A
5965168	Mesens et al.	Oct 1999	A
5972370	Eckenhoff et al.	Oct 1999	A
5972373	Yajima et al.	Oct 1999	A
5976109	Heruth	Nov 1999	A
5980945	Ruiz	Nov 1999	A
5981719	Woiszwillo et al.	Nov 1999	A
5984890	Gast et al.	Nov 1999	A
5985305	Peery et al.	Nov 1999	A
5989463	Tracy et al.	Nov 1999	A
5997527	Gumucio et al.	Dec 1999	A
5997902	Maruyama et al.	Dec 1999	A
6007805	Foster et al.	Dec 1999	A
6017545	Modi	Jan 2000	A
6022561	Carlsson et al.	Feb 2000	A
6023802	King	Feb 2000	A
6029361	Newman	Feb 2000	A
6053927	Hamas	Apr 2000	A
6060450	Soos et al.	May 2000	A
6069133	Carlo et al.	May 2000	A
6074377	Sanfilippo, II	Jun 2000	A
6074660	Jamiolkowski et al.	Jun 2000	A
6074673	Guillen	Jun 2000	A
6100346	Jamiolkowski et al.	Aug 2000	A
6110503	Rickey et al.	Aug 2000	A
D430671	Shute	Sep 2000	S
6113938	Chen et al.	Sep 2000	A
6113947	Cleland et al.	Sep 2000	A
6120787	Gustafsson et al.	Sep 2000	A
6124261	Stevenson et al.	Sep 2000	A
6124281	Lewis et al.	Sep 2000	A
6127520	Ueda et al.	Oct 2000	A
6129761	Hubbell	Oct 2000	A
6130200	Brodbeck et al.	Oct 2000	A
6132420	Dionne et al.	Oct 2000	A
6133249	Hills	Oct 2000	A
6133429	Davis et al.	Oct 2000	A
6146139	Harrison, III	Nov 2000	A
6147168	Jamiolkowski et al.	Nov 2000	A
6156331	Peery et al.	Dec 2000	A
6172046	Albrecht	Jan 2001	B1
6174547	Dong et al.	Jan 2001	B1
6177096	Zerbe et al.	Jan 2001	B1
6183461	Matsuura et al.	Feb 2001	B1
6187095	Labrecque et al.	Feb 2001	B1
6190350	Davis et al.	Feb 2001	B1
6190700	Okada et al.	Feb 2001	B1
6190702	Takada et al.	Feb 2001	B1
6191102	DiMarchi et al.	Feb 2001	B1
6204022	Johnson et al.	Mar 2001	B1
6217893	Pellet et al.	Apr 2001	B1
6217906	Gumucio et al.	Apr 2001	B1
6217908	Mathiowitz et al.	Apr 2001	B1
6218431	Schoen et al.	Apr 2001	B1
6224894	Jamiolkowski et al.	May 2001	B1
6235712	Stevenson et al.	May 2001	B1
6245349	Yiv et al.	Jun 2001	B1
6245357	Edgren et al.	Jun 2001	B1
6248112	Gambale et al.	Jun 2001	B1
6251435	Jamiolkowski et al.	Jun 2001	B1
D445975	Stratford	Jul 2001	S
6258377	New et al.	Jul 2001	B1
6261584	Peery et al.	Jul 2001	B1
6268343	Knudsen et al.	Jul 2001	B1
6270700	Ignatious	Aug 2001	B1
6270787	Ayer	Aug 2001	B1
6277413	Sankaram	Aug 2001	B1
6283949	Roorda	Sep 2001	B1
6284264	Zerbe et al.	Sep 2001	B1
6284727	Kim et al.	Sep 2001	B1
6287295	Chen et al.	Sep 2001	B1
6284725	Coolidge et al.	Dec 2001	B1
6329336	Bridon et al.	Dec 2001	B1
6331311	Brodbeck et al.	Dec 2001	B1
6372218	Cummins, Jr.	Apr 2002	B1
6372256	Jamiolkowski et al.	Apr 2002	B2
6375978	Kleiner et al.	Apr 2002	B1
D456776	Lindekugel	May 2002	S
6395282	Kende et al.	May 2002	B1
6395292	Peery et al.	May 2002	B2
6402716	Ryoo et al.	Jun 2002	B1
6403655	Bezwada et al.	Jun 2002	B1
6419952	Wong et al.	Jul 2002	B2
6428517	Hochman et al.	Aug 2002	B1
6433144	Morris et al.	Aug 2002	B1
6436091	Harper et al.	Aug 2002	B1
6447522	Garnbale et al.	Sep 2002	B2
6451974	Hansen	Sep 2002	B1
6458385	Jamiolkowski et al.	Oct 2002	B2
6458387	Scott et al.	Oct 2002	B1
6458924	Knudsen et al.	Oct 2002	B2
6461605	Cutler et al.	Oct 2002	B1
6464688	Harper et al.	Oct 2002	B1
6468961	Brodbeck et al.	Oct 2002	B1
6471688	Harper et al.	Oct 2002	B1
6472512	LaFleur et al.	Oct 2002	B1
6478768	Kneer	Nov 2002	B1
6485706	McCoy et al.	Nov 2002	B1
6495164	Ramstack et al.	Dec 2002	B1
6506724	Hiles et al.	Jan 2003	B1
6508808	Carr et al.	Jan 2003	B1
6514500	Bridon et al.	Feb 2003	B1
6514517	Jamilolkowski et al.	Feb 2003	B2
6524305	Peterson et al.	Feb 2003	B1
6528093	Kamei et al.	Mar 2003	B1
6528486	Larsen et al.	Mar 2003	B1
D472896	Peiker	Apr 2003	S
6541021	Johnson et al.	Apr 2003	B1
6544239	Kinsey et al.	Apr 2003	B2
6544252	Theeuwes et al.	Apr 2003	B1
6547250	Noble	Apr 2003	B1
6551613	Dong et al.	Apr 2003	B1
6569420	Chen et al.	May 2003	B2
6572890	Faour et al.	Jun 2003	B2
6579851	Goeke et al.	Jun 2003	B2
6589157	Fontayne et al.	Jul 2003	B2
6592508	Ravins et al.	Jul 2003	B1
6592887	Zerbe et al.	Jul 2003	B2
6593295	Bridon et al.	Jul 2003	B2
6607529	Jones et al.	Aug 2003	B1
6626863	Berler	Sep 2003	B1
6635268	Peery et al.	Oct 2003	B2
6645192	Kenison et al.	Nov 2003	B2
6667061	Rarnstack et al.	Dec 2003	B2
6670368	Breault et al.	Dec 2003	B1
6673767	Brodbeck et al.	Jan 2004	B1
6682522	Carr et al.	Jan 2004	B2
6703225	Kojima et al.	Mar 2004	B1
6703359	Young et al.	Mar 2004	B1
6706689	Coolidge et al.	Mar 2004	B2
6709671	Zerbe et al.	Mar 2004	B2
6720407	Hughes et al.	Apr 2004	B1
6730328	Maskiwicz et al.	May 2004	B2
6767887	Hoffmann et al.	Jul 2004	B1
6821949	Bridon et al.	Nov 2004	B2
6833256	Pontzer et al.	Dec 2004	B1
6835194	Johnson et al.	Dec 2004	B2
6840931	Peterson et al.	Jan 2005	B2
6849708	Habener	Feb 2005	B1
6849714	Bridon et al.	Feb 2005	B1
6858576	Young et al.	Feb 2005	B1
6872700	Young et al.	Mar 2005	B1
6875748	Manthorpe et al.	Apr 2005	B2
6887470	Bridon et al.	May 2005	B1
6887849	Bridon et al.	May 2005	B2
6899887	Ayer	May 2005	B2
6899898	Albayrak	May 2005	B2
6902744	Kolterman et al.	Jun 2005	B1
6903186	Dong	Jun 2005	B1
6913767	Cleland et al.	Jul 2005	B1
6923800	Chen et al.	Aug 2005	B2
6924264	Prickett et al.	Aug 2005	B1
6939556	Lautenbach	Sep 2005	B2
6956026	Beeley et al.	Oct 2005	B2
6960192	Flaherty et al.	Nov 2005	B1
6969702	Bertilsson et al.	Nov 2005	B2
6976981	Ayer	Dec 2005	B2
6989366	Beeley et al.	Jan 2006	B2
6992065	Okumu	Jan 2006	B2
6997922	Theeuwes et al.	Feb 2006	B2
7008439	Janzen et al.	Mar 2006	B1
7014636	Gilbert	Mar 2006	B2
7022674	DeFelippis et al.	Apr 2006	B2
7041646	Pan et al.	May 2006	B2
7074423	Fereira et al.	Jul 2006	B2
7084243	Glaesner et al.	Aug 2006	B2
7101567	Sano et al.	Sep 2006	B1
7101843	Glaesner et al.	Sep 2006	B2
7112335	Lautenbach	Sep 2006	B2
7115569	Beeley et al.	Oct 2006	B2
7138375	Beeley et al.	Nov 2006	B2
7138486	Habener	Nov 2006	B2
7141547	Rosen et al.	Nov 2006	B2
7144863	DeFelippis et al.	Dec 2006	B2
7153825	Young et al.	Dec 2006	B2
7157555	Beeley et al.	Jan 2007	B1
7163688	Peery et al.	Jan 2007	B2
7163697	Hanes et al.	Jan 2007	B2
7199217	DiMarchi et al.	Apr 2007	B2
7205409	Pei et al.	Apr 2007	B2
7207982	Dionne et al.	Apr 2007	B2
7214206	Rue et al.	May 2007	B2
7241457	Chen et al.	Jul 2007	B2
7258869	Berry et al.	Aug 2007	B1
D555589	Hussaini	Nov 2007	S
7297761	Beeley et al.	Nov 2007	B2
7316680	Gilbert	Jan 2008	B2
7393827	Nadler	Jul 2008	B2
7407499	Trautman	Aug 2008	B2
7442682	Kitaura et al.	Oct 2008	B2
7456254	Wright et al.	Nov 2008	B2
7459432	Cowley et al.	Dec 2008	B2
7521423	Young et al.	Apr 2009	B2
7563871	Wright et al.	Jul 2009	B2
7589169	Bolotin	Sep 2009	B2
7604647	Chen	Oct 2009	B2
7612176	Wright et al.	Nov 2009	B2
7632256	Mosler et al.	Dec 2009	B2
7635463	Bolotin et al.	Dec 2009	B2
D608447	Meyer	Jan 2010	S
7655254	Dennis et al.	Feb 2010	B2
7655257	Peery et al.	Feb 2010	B2
7666835	Bloom et al.	Feb 2010	B2
7682356	Alessi et al.	Mar 2010	B2
7727519	Moran	Jun 2010	B2
7731947	Eliaz et al.	Jun 2010	B2
7736665	Patel et al.	Jun 2010	B2
7741269	Young et al.	Jun 2010	B2
7766924	Bombard et al.	Aug 2010	B1
7790140	Bolotin	Sep 2010	B2
7825091	Bloom et al.	Nov 2010	B2
7829109	Chen et al.	Nov 2010	B2
7833543	Gibson et al.	Nov 2010	B2
7879028	Alessi et al.	Feb 2011	B2
7879794	Berry et al.	Apr 2011	B2
7919109	Berry et al.	Apr 2011	B2
D638478	Block	May 2011	S
7928065	Rohloff et al.	Jun 2011	B2
7964183	Eliaz et al.	Jun 2011	B2
8039432	Bridon et al.	Oct 2011	B2
7959938	Lautenbach et al.	Nov 2011	B2
8048438	Berry et al.	Nov 2011	B2
8052996	Lautenbach et al.	Nov 2011	B2
8058233	Cowley et al.	Nov 2011	B2
8101576	Bloom	Jan 2012	B2
8114430	Rohloff et al.	Feb 2012	B2
8114437	Rohloff et al.	Feb 2012	B2
8158150	Lautenbach et al.	Apr 2012	B2
8173150	Berry et al.	May 2012	B2
8202836	Moore et al.	Jun 2012	B2
8206745	Rohloff et al.	Jun 2012	B2
8211467	Rohloff et al.	Jul 2012	B2
8217001	Cowley et al.	Jul 2012	B2
8231859	Bolotin et al.	Jul 2012	B2
8251946	Bardy	Aug 2012	B2
8257682	Bolotin et al.	Sep 2012	B2
8257691	Eliaz et al.	Sep 2012	B2
8263545	Bloom	Sep 2012	B2
8263736	Berry	Sep 2012	B2
8268341	Berry	Sep 2012	B2
8273365	Lautenbach et al.	Sep 2012	B2
8273713	Pittner et al.	Sep 2012	B2
D669589	Delaey	Oct 2012	S
8277776	Bolotin et al.	Oct 2012	B2
8278267	Weyer et al.	Oct 2012	B2
8288338	Alessi et al.	Oct 2012	B2
8298561	Alessi et al.	Oct 2012	B2
8299025	Alessi et al.	Oct 2012	B2
8343140	Alessi et al.	Jan 2013	B2
8367095	Lautenbach et al.	Feb 2013	B2
8372424	Berry et al.	Feb 2013	B2
D678889	Chiu	Mar 2013	S
8398967	Eliaz et al.	Mar 2013	B2
8440226	Rohloff et al.	May 2013	B2
8454552	Bardy	Jun 2013	B2
8460694	Rohloff et al.	Jun 2013	B2
8470353	Lautenbach et al.	Jun 2013	B2
8556861	Tsals	Oct 2013	B2
8722037	Veenstra et al.	May 2014	B2
8747412	Bae et al.	Jun 2014	B2
8801700	Alessi et al.	Aug 2014	B2
8815802	Kalthoff et al.	Aug 2014	B2
8845726	Tebbe	Sep 2014	B2
8858621	Oba	Oct 2014	B2
8865202	Zerbe et al.	Oct 2014	B2
8888745	Van Der Graaf et al.	Nov 2014	B2
8926595	Alessi et al.	Jan 2015	B2
8940316	Alessi et al.	Jan 2015	B2
8992961	Berry et al.	Mar 2015	B2
8992962	Lautenbach et al.	Mar 2015	B2
9044209	Dayton et al.	Jun 2015	B2
9078900	Kuzma et al.	Jul 2015	B2
9095553	Rohloff et al.	Aug 2015	B2
9241722	Yu	Jan 2016	B2
D750764	DeSocio	Mar 2016	S
9332995	Russo	May 2016	B2
9526763	Rohloff et al.	Dec 2016	B2
9539200	Lautenbach	Jan 2017	B2
9572889	Alessi et al.	Feb 2017	B2
D789539	Kleiner	Jun 2017	S
D789540	Gyorgy	Jun 2017	S
9682127	Alessi et al.	Jun 2017	B2
RE46577	Collins	Oct 2017	E
D805199	Chen	Dec 2017	S
D810289	Jutila	Feb 2018	S
9889085	Alessi et al.	Feb 2018	B1
9931133	Mirza	Apr 2018	B2
D816843	Lewis	May 2018	S
D819820	Radau	Jun 2018	S
20010012511	Bezwada et al.	Aug 2001	A1
20010021377	Jamiolkowski et al.	Sep 2001	A1
20010021822	Ayer	Sep 2001	A1
20010022974	Ayer	Sep 2001	A1
20010026793	Jamiolkowski et al.	Oct 2001	A1
20010027311	Chen et al.	Oct 2001	A1
20010031940	Loos	Oct 2001	A1
20010031790	Beisswenger	Nov 2001	A1
20010036472	Wong et al.	Nov 2001	A1
20010040326	Balczun	Nov 2001	A1
20020001631	Okumu	Jan 2002	A1
20020004481	Cleland et al.	Jan 2002	A1
20020012818	Ruppi et al.	Jan 2002	A1
20020034532	Brodbeck et al.	Mar 2002	A1
20020037309	Jaworowicz et al.	Mar 2002	A1
20020048600	Bhatt et al.	Apr 2002	A1
20020077599	Wojcik	Jun 2002	A1
20020098180	Lei	Jul 2002	A1
20020136848	Yoshii et al.	Sep 2002	A1
20020137666	Beeley et al.	Sep 2002	A1
20020141985	Pittner et al.	Oct 2002	A1
20020197185	Jamiolkowski et al.	Dec 2002	A1
20020197235	Moran	Dec 2002	A1
20030007992	Gibson et al.	Jan 2003	A1
20030032947	Harper et al.	Feb 2003	A1
20030040699	Talling	Feb 2003	A1
20030044467	Brodbeck et al.	Mar 2003	A1
20030045454	Okumu et al.	Mar 2003	A1
20030059376	Libbey et al.	Mar 2003	A1
20030059471	Compton et al.	Mar 2003	A1
20030060425	Ahlem et al.	Mar 2003	A1
20030078618	Fey et al.	Apr 2003	A1
20030097121	Babcock et al.	Jun 2003	A1
20030104063	Babcock et al.	Jun 2003	A1
20030108608	Berry et al.	Jun 2003	A1
20030108609	Berry et al.	Jun 2003	A1
20030113380	Ramstack et al.	Jun 2003	A1
20030114837	Peterson et al.	Jun 2003	A1
20030118660	Rickey et al.	Jun 2003	A1
20030135153	Hagemeier	Jul 2003	A1
20030138403	Drustrup	Jul 2003	A1
20030138491	Tracy et al.	Jul 2003	A1
20030157178	Chen et al.	Aug 2003	A1
20030170289	Chen et al.	Sep 2003	A1
20030180364	Chen et al.	Sep 2003	A1
20030186858	Arentsen	Oct 2003	A1
20030191099	Bohlmann et al.	Oct 2003	A1
20030211974	Brodbeck et al.	Nov 2003	A1
20030215515	Truong-Le et al.	Nov 2003	A1
20030220617	Dickerson	Nov 2003	A1
20030233101	Lubock et al.	Dec 2003	A1
20040001689	Goldsmith et al.	Jan 2004	A1
20040001889	Chen et al.	Jan 2004	A1
20040002442	Pan et al.	Jan 2004	A1
20040022859	Chen et al.	Feb 2004	A1
20040024068	Chen et al.	Feb 2004	A1
20040024069	Chen et al.	Feb 2004	A1
20040029784	Hathaway	Feb 2004	A1
20040039376	Peery et al.	Feb 2004	A1
20040047888	Kenison et al.	Mar 2004	A1
20040097906	Fereira et al.	May 2004	A1
20040101557	Gibson et al.	May 2004	A1
20040102762	Gilbert	May 2004	A1
20040115236	Chan et al.	Jun 2004	A1
20040142867	Oi et al.	Jul 2004	A1
20040142902	Struijker-Boudier	Jul 2004	A1
20040151753	Chen et al.	Aug 2004	A1
20040157951	Wolf	Aug 2004	A1
20040198654	Glaesner et al.	Oct 2004	A1
20040199140	Rue	Oct 2004	A1
20040209801	Brand et al.	Oct 2004	A1
20040215133	Weber et al.	Oct 2004	A1
20040224903	Berry et al.	Nov 2004	A1
20040225113	LaFleur et al.	Nov 2004	A1
20040243106	Ayer	Dec 2004	A1
20040265273	Li et al.	Dec 2004	A1
20040266683	Hathaway et al.	Dec 2004	A1
20040266692	Young et al.	Dec 2004	A1
20050004557	Russell	Jan 2005	A1
20050008661	Fereira et al.	Jan 2005	A1
20050009742	Bertilsson et al.	Jan 2005	A1
20050010196	Fereira et al.	Jan 2005	A1
20050070883	Brown et al.	Mar 2005	A1
20050079200	Rathenow et al.	Apr 2005	A1
20050079202	Chen et al.	Apr 2005	A1
20050010942	Eliaz et al.	May 2005	A1
20050095284	Trautman	May 2005	A1
20050101943	Ayer et al.	May 2005	A1
20050106214	Chen	May 2005	A1
20050112188	Eliaz et al.	May 2005	A1
20050118206	Luk et al.	Jun 2005	A1
20050118221	Blakely et al.	Jun 2005	A1
20050131386	Freeman et al.	Jun 2005	A1
20050131389	Peterson et al.	Jun 2005	A1
20050143749	Zalenski et al.	Jun 2005	A1
20050175701	Pan et al.	Aug 2005	A1
20050201980	Moran	Sep 2005	A1
20050215475	Ong et al.	Sep 2005	A1
20050266087	Junnarkar et al.	Dec 2005	A1
20050271702	Wright et al.	Dec 2005	A1
20050276856	Fereira et al.	Dec 2005	A1
20050281879	Chen et al.	Dec 2005	A1
20060013879	Brodbeck et al.	Jan 2006	A9
20060014678	Cowley et al.	Jan 2006	A1
20060030526	Liu et al.	Feb 2006	A1
20060069029	Kolterman et al.	Mar 2006	A1
20060073182	Wong et al.	Apr 2006	A1
20060084604	Kitaura et al.	Apr 2006	A1
20060094652	Levy et al.	May 2006	A1
20060094693	Aziz et al.	May 2006	A1
20060141040	Chen et al.	Jun 2006	A1
20060142234	Chen et al.	Jun 2006	A1
20060160736	Nadler	Jul 2006	A1
20060178304	Juul-Mortensen et al.	Aug 2006	A1
20060193918	Rohloff et al.	Aug 2006	A1
20060216242	Rohloff et al.	Sep 2006	A1
20060224145	Gills	Oct 2006	A1
20060233841	Brodbeck et al.	Oct 2006	A1
20060246138	Rohloff et al.	Nov 2006	A1
20060251618	Dennis et al.	Nov 2006	A1
20060263433	Ayer et al.	Nov 2006	A1
20060264890	Moberg et al.	Nov 2006	A1
20060280795	Penhasi et al.	Dec 2006	A1
20060293232	Levy et al.	Dec 2006	A1
20070027105	Junnarkar et al.	Feb 2007	A1
20070141102	De Graaff et al.	Jun 2007	A1
20070149011	Kent et al.	Jun 2007	A1
20070166352	Wright et al.	Jul 2007	A1
20070207958	Bridon et al.	Sep 2007	A1
20070248572	Moran et al.	Oct 2007	A1
20070281024	Lautenbach et al.	Dec 2007	A1
20080020016	Li et al.	Jan 2008	A1
20080038316	Wong et al.	Feb 2008	A1
20080064636	Bloom et al.	Mar 2008	A1
20080091176	Alessi et al.	Apr 2008	A1
20080110515	Angelosanto et al.	May 2008	A1
20080112994	Junnarkar	May 2008	A1
20080200383	Jennings et al.	Aug 2008	A1
20080207512	Roth et al.	Aug 2008	A1
20080208194	Bickenbach	Aug 2008	A1
20080226625	Berry et al.	Sep 2008	A1
20080226689	Berry et al.	Sep 2008	A1
20080260838	Hokenson et al.	Oct 2008	A1
20080260840	Alessi et al.	Oct 2008	A1
20080269725	Deem et al.	Oct 2008	A1
20080312157	Levy et al.	Dec 2008	A1
20090012463	Beelen et al.	Jan 2009	A1
20090022727	Houston et al.	Jan 2009	A1
20090036364	Levy et al.	Feb 2009	A1
20090042781	Petersen et al.	Feb 2009	A1
20090074734	Rottiers	Mar 2009	A1
20090087408	Berry et al.	Apr 2009	A1
20090125030	Tebbe	May 2009	A1
20090156474	Roth et al.	Jun 2009	A1
20090163447	Maggio	Jun 2009	A1
20090186817	Ghosh et al.	Jul 2009	A1
20090202481	Li et al.	Aug 2009	A1
20090202608	Alessi et al.	Aug 2009	A1
20090209460	Young et al.	Aug 2009	A1
20090210019	Kim et al.	Aug 2009	A1
20090215694	Kolterman et al.	Aug 2009	A1
20090234392	Dziedzic	Sep 2009	A1
20090247463	Wright et al.	Oct 2009	A1
20090254143	Tweden et al.	Oct 2009	A1
20090286723	Levy et al.	Nov 2009	A1
20090312246	Baron et al.	Dec 2009	A1
20100092566	Alessi et al.	Apr 2010	A1
20100094252	Wengreen et al.	Apr 2010	A1
20100105627	Salama et al.	Apr 2010	A1
20100144621	Kim et al.	Jun 2010	A1
20100185184	Alessi et al.	Jul 2010	A1
20100297209	Rohloff et al.	Nov 2010	A1
20100298807	Jansen et al.	Nov 2010	A1
20100331868	Bardy	Dec 2010	A1
20110076317	Alessi et al.	Mar 2011	A1
20110104111	Rohloff et al.	May 2011	A1
20110152181	Alsina-Fernandez et al.	Jun 2011	A1
20110152182	Alsina-Fernandez et al.	Jun 2011	A1
20110160708	Berry et al.	Jun 2011	A1
20110166554	Alessi et al.	Jul 2011	A1
20110264077	Rohloff et al.	Oct 2011	A1
20110306549	Tatarkiewicz et al.	Dec 2011	A1
20120178687	Alessi et al.	Jul 2012	A1
20120208755	Leung	Aug 2012	A1
20120265232	Surbone	Oct 2012	A1
20120303045	Cooper et al.	Nov 2012	A1
20130030417	Alessi	Jan 2013	A1
20130034210	Rohloff et al.	Feb 2013	A1
20130052237	Eliaz et al.	Feb 2013	A1
20130296661	Bornzin et al.	Nov 2013	A1
20130324977	Vanderpool	Dec 2013	A1
20140058409	Bratlie	Feb 2014	A1
20140148837	Levitan	May 2014	A1
20140163057	Patel et al.	Jun 2014	A1
20140236162	Barongan	Aug 2014	A1
20140324067	Emken	Oct 2014	A1
20140378900	Alessi et al.	Dec 2014	A1
20150111818	Alessi et al.	Jan 2015	A1
20150057227	Leung	Feb 2015	A1
20150231062	Lautenbach et al.	Aug 2015	A1
20150231256	Berry et al.	Aug 2015	A1
20150297509	Schwarz	Oct 2015	A1
20150359553	Harnisch	Dec 2015	A1
20160022582	Alessi et al.	Jan 2016	A1
20160030337	Kuzma	Feb 2016	A1
20160354115	Smith et al.	Dec 2016	A1
20160354305	Alessi et al.	Dec 2016	A1
20170056476	Rohloff et al.	Mar 2017	A1
20170079906	Alessi et al.	Mar 2017	A1
20170119854	Alessi et al.	May 2017	A1
20170119855	Berry et al.	May 2017	A1
20170181964	Lautenbach et al.	Jun 2017	A1
20170252409	Leung	Sep 2017	A1
20170273706	Mirza	Sep 2017	A1
20170319470	Eliaz et al.	Nov 2017	A1
20170319662	Berry et al.	Nov 2017	A1
20170348392	Rohloff et al.	Dec 2017	A1
20170368145	Alessi et al.	Dec 2017	A1
20180009871	Blackwell et al.	Jan 2018	A1
20180193059	Bae	Jul 2018	A1

Foreign Referenced Citations (203)

Number	Date	Country
000000635692	Sep 1936	DE
0079405	May 1983	EP
0254394	Jan 1988	EP
0295411	Dec 1988	EP
0304107	Feb 1989	EP
0368339	May 1990	EP
0373867	Jun 1990	EP
0431942	Jun 1991	EP
0486959	May 1992	EP
0497575	Aug 1992	EP
0521586	Jan 1993	EP
0596161	May 1994	EP
0379147	Sep 1994	EP
0627231	Dec 1994	EP
0631794	Jan 1995	EP
0729747	May 1997	EP
0771817	May 1997	EP
0596161	Feb 1998	EP
0841359	May 1998	EP
0767689	Jun 1999	EP
1046399	Oct 2000	EP
1084703	Mar 2001	EP
1300129	Apr 2003	EP
1300173	Apr 2003	EP
1300129	May 2003	EP
1323450	Jul 2003	EP
1600187	Jan 2009	EP
2133073	Dec 2009	EP
2020990	Sep 2010	EP
640907	Jul 1928	FR
2616665	Dec 1988	FR
1049104	Nov 1966	GB
1518683	Jul 1978	GB
2138298	Nov 1986	GB
2501400	Oct 2013	GB
H02124814	May 1990	JP
H07196479	Aug 1995	JP
1997509346	Sep 1997	JP
9241153	Sep 1997	JP
11-100353	Apr 1999	JP
2006213727	Aug 2006	JP
8901004	Nov 1990	NL
9000948	Nov 1990	NL
9100160	Aug 1992	NL
9100160	Aug 1992	NL
592113	Aug 2012	NZ
200634060	Oct 2006	TW
WO-1989003678	May 1989	WO
WO-1990013285	Nov 1990	WO
WO-1990013361	Nov 1990	WO
WO-1990013780	Nov 1990	WO
WO 9107160	May 1991	WO
WO-1992019241	Nov 1992	WO
WO 9306819	Apr 1993	WO
WO 9306821	Apr 1993	WO
WO 93008832	May 1993	WO
WO 9309763	May 1993	WO
WO 9323083	Nov 1993	WO
WO 9409743	May 1994	WO
WO-1994010982	May 1994	WO
WO 9421262	Sep 1994	WO
WO 9501167	Jan 1995	WO
WO 9509006	Apr 1995	WO
WO 9509007	Apr 1995	WO
WO-1995013799	May 1995	WO
WO 9534285	Dec 1995	WO
WO 96001134	Jan 1996	WO
WO 96003116	Feb 1996	WO
WO-1996036317	Nov 1996	WO
WO 9639142	Dec 1996	WO
WO 9640049	Dec 1996	WO
WO 9640139	Dec 1996	WO
WO 9640355	Dec 1996	WO
WO-1996040049	Dec 1996	WO
WO 9715289	May 1997	WO
WO 9715296	May 1997	WO
WO 9728181	Aug 1997	WO
WO-1997031943	Sep 1997	WO
WO-1997044039	Nov 1997	WO
WO 9746204	Dec 1997	WO
WO 9747339	Dec 1997	WO
WO 9800152	Jan 1998	WO
WO 9800157	Jan 1998	WO
WO 9800158	Jan 1998	WO
WO 9802169	Jan 1998	WO
WO-1997041837	Feb 1998	WO
WO-1998007412	Feb 1998	WO
WO 9813092	Apr 1998	WO
WO 9816250	Apr 1998	WO
WO 9817315	Apr 1998	WO
WO 199813091	Apr 1998	WO
WO 9820930	May 1998	WO
WO 9827960	Jul 1998	WO
WO 98027962	Jul 1998	WO
WO 9827963	Jul 1998	WO
WO 98030231	Jul 1998	WO
WO 9832463	Jul 1998	WO
WO-1998030231	Jul 1998	WO
WO 9842317	Oct 1998	WO
WO 9847487	Oct 1998	WO
WO 9851282	Nov 1998	WO
WO 9858698	Dec 1998	WO
WO 9903453	Jan 1999	WO
WO 9904767	Feb 1999	WO
WO 99004768	Feb 1999	WO
WO-1999012549	Mar 1999	WO
WO 9916419	Apr 1999	WO
WO 99025728	May 1999	WO
WO 9929306	Jun 1999	WO
WO 99033446	Jul 1999	WO
WO 9933449	Jul 1999	WO
WO 9939700	Aug 1999	WO
WO 99040788	Aug 1999	WO
WO 99044659	Sep 1999	WO
WO 99062501	Dec 1999	WO
WO 99064061	Dec 1999	WO
WO 00013663	Mar 2000	WO
WO 00029206	May 2000	WO
WO 00038652	Jul 2000	WO
WO 00039280	Jul 2000	WO
WO 00040273	Jul 2000	WO
WO 00041548	Jul 2000	WO
WO 00045790	Aug 2000	WO
WO 00054745	Sep 2000	WO
WO-2000059476	Oct 2000	WO
WO 00066138	Nov 2000	WO
WO 00067728	Nov 2000	WO
WO-2000066087	Nov 2000	WO
WO-2001019345	Mar 2001	WO
WO 0128631	Apr 2001	WO
WO-2001028525	Apr 2001	WO
WO 01043528	Jun 2001	WO
WO 01051041	Jul 2001	WO
WO 0168168	Sep 2001	WO
WO 0178683	Oct 2001	WO
WO 02028366	Apr 2002	WO
WO 02036072	May 2002	WO
WO 02043800	Jun 2002	WO
WO 02045752	Jun 2002	WO
WO 0247716	Jun 2002	WO
WO 02067895	Sep 2002	WO
WO 02069983	Sep 2002	WO
WO 0276344	Oct 2002	WO
WO 02085428	Oct 2002	WO
WO 03000230	Jan 2003	WO
WO 03007981	Jan 2003	WO
WO 03011892	Feb 2003	WO
WO 03024357	Mar 2003	WO
WO 03024503	Mar 2003	WO
WO-2003020245	Mar 2003	WO
WO 03030923	Apr 2003	WO
WO 03041684	May 2003	WO
WO 03041757	May 2003	WO
WO 03053400	Jul 2003	WO
WO-2003066585	Aug 2003	WO
WO 03072113	Sep 2003	WO
WO 03072133	Sep 2003	WO
WO 04002565	Jan 2004	WO
WO 2004026106	Apr 2004	WO
WO-2004034975	Apr 2004	WO
WO-2004035754	Apr 2004	WO
WO-2004035762	Apr 2004	WO
WO-2004036186	Apr 2004	WO
WO 04046338	Jun 2004	WO
WO 04052336	Jun 2004	WO
WO 04056338	Jul 2004	WO
WO 04089335	Oct 2004	WO
WO 2004089458	Oct 2004	WO
WO-2004103342	Dec 2004	WO
WO 05048930	Jun 2005	WO
WO 05048952	Jun 2005	WO
WO 05102293	Nov 2005	WO
WO-2005102293	Nov 2005	WO
WO-2005110425	Nov 2005	WO
WO 06017772	Feb 2006	WO
WO 06023526	Mar 2006	WO
WO 2006077242	Jul 2006	WO
WO 2006077250	Jul 2006	WO
WO 06081279	Aug 2006	WO
WO 06083761	Aug 2006	WO
WO 06084139	Aug 2006	WO
WO 06086727	Aug 2006	WO
WO 06101815	Sep 2006	WO
WO 06111169	Oct 2006	WO
WO-2006131730	Dec 2006	WO
WO 07024700	Mar 2007	WO
WO 07056681	May 2007	WO
WO 07075534	Jul 2007	WO
WO 07084460	Jul 2007	WO
WO 2007082889	Jul 2007	WO
WO 07133778	Nov 2007	WO
WO 07140416	Dec 2007	WO
WO 08021133	Feb 2008	WO
WO-2008041245	Apr 2008	WO
WO 08061355	May 2008	WO
WO-2008086086	Jul 2008	WO
WO 08133908	Nov 2008	WO
WO 08134425	Nov 2008	WO
WO 09109927	Sep 2009	WO
WO-2009143285	Nov 2009	WO
WO 2010045169	Apr 2010	WO
WO 2013004983	Jan 2013	WO
WO 2013184235	Dec 2013	WO

Non-Patent Literature Citations (256)

Entry
“Abstracts 2007,” Diabetologia Clinical & Experimental Diabetes & Metabolism, Springer, Berlin, Germany, vol. 50 S243 (Aug. 21, 2007) (paragraph [0586]) (XP002538652).
Jetschmann et al., “Open-label rising-dose study of omega interferon in IFN-naive patients with chronic hepatitis C,” Gastroenterology 122:A278-A347 (Apr. 1, 2002) (Abstract M1454).
Bray, “Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin,” (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME).
“Implantable infusion pumps: technology poised for takeoff,” BBI Newsletter 17(12):209-211 (Dec. 1994).
“Search Report and Written Opinion” dated Dec. 19, 2008 for PCT/US2008/005235, filed Apr. 22, 2008.
Adamson et al., “Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer,” J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997).
Adolf et al., “Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN- ω1 is a component of human leukocyte IFN,” Virology 175(2):410-471 (Apr. 1990).
Adolf et al., “Antigenic structure of human interferon ω1 (Interferon α11 1): comparison with other human interferons,” J. Gen. Virol. 68(6):1669-1676 (Jun. 1987).
Adolf et al., “Purification and characterization of natural human interferon ω1,” J. Bio. Chem. 265(16):9290-9295 (Jun. 1990).
Adolf et al., “Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein,” Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991).
ANDRX Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005).
ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984).
Ansel et al., “Dosage Form Design: Pharmaceutical and Formulation Considerations,” Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999).
Ansel et al., “Modified-Release Dosage Forms and Drug Delivery Systems,” Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999).
Aulitzky, “Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama,” Journal of Clinical Oncology 7(12):1875-1884 (1989).
Hauck, “Engineer's Guide to Plastics,” Materials Engineering 5(72):38-45 (Jul. 17, 1972).
Bailon et al., “Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C,” Bioconjugate Chemistry 12(2):195-202 (2001).
Bakan et al., “Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography,” J. Pharm. Sci., 85(9):908-914 (1996).
Bakhtiar et al, “Taking Delivery,” Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems).
Balkwill,F., “Interferons,” Lancet 1(8646):1060-1063 (May 1989).
Bauer et al., “Non-aqueous emulsions as vehicles for capsule fillings,” Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984).
Bekkering et al., “Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model,” Hepatology 33(2):419-423 (Feb. 2001).
Bell et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,” Nature 302:716-718 (1983).
Bell et al, “Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin,” Drug Delivery Research & Dev. Biopolymers, (35):201-209 (1995).
Bertoncello et al., “Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil,” Int. J. Radiat. Biol. 67(1):57-64 (1995).
Bohlinder et al., “Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system,” Euro. J. Pharm. Sci. 2(4):271-279 (1994).
Bolinger et al., “Recombinant interferon γ for treatment of chronic granulomatous disease and other disorders,” Clin. Pharm. 11(10):834-850 (Oct. 1992).
Bonkovsky et al., “Outcomes research in chronic viral hepatitis C: effects of interferon therapy,” Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000).
Borden et al., “Second-generation interferons for cancer: clinical targets,” Semin. Cancer Biol. 10(2):125-144 (Apr. 2000).
Boué et al., “Antiviral and antiluteolytic activity of recombinant bovine IFN-ω1 obtained from Pichia pastoris,” J. Interferon & Cytokine Res. 20:677-683 (2000).
Buckwold et. al. “Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses,” Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006).
Cantor, “Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence,” J. Chem. Physics 104(20):8082-8095 (1996).
CAS No. 56-81-5 (Nov. 16, 1984).
Chang et al., “Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer,” Pharm. Tech. 20(1):80-84 (1996).
Chapman et al., “Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins),” Chem. & Physics of Lipids 1(5):445-475 (1967).
Chaumeil, “Micronization: a method of improving the bioavailability of poorly soluble drugs,” Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998).
Clark et al., “The diabetic Zucker fatty rat,” Proc. Soc. Exp. Biol. 173(1):68-75 (1983).
Condino-Neto, “Interferon-γ improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation,” Blood 95(11):3548-3554 (Jun. 2000).
Darney, “Subdermal progestin implant contraception,” Current Opinion in Obstetrics & Gynecology 3:470-476 (1991).
Das et al., “Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues,” BioPharm, 2(11):44-51 (1999).
Dash et al., “Therapeutic applications of implantable drug delivery systems,” Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998).
Davis et al., “Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570 ).
Deacon et al., “GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion,” Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002).
Desai et al., “Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor,” J. Am. Chem. Soc. 116(21):9420-9422 (1994).
Di Marco et al., “Combined treatment of relapse of chronic hepatitis C with high-dose α-2B interferon plus ribavirin for 6 or 12 months,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569).
Dorr et al., “Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days,” J. Interferon Res. 8:717-725 (1988).
Uhlig et al., “The electro-osmotic actuation of implantable insulin micropumps,” J. Biomed. Materials Res. 17:931-943 (1983).
Efendic et al., “Overview of incretin hormones,” Horm. Metab. Res., 36(11-12):742-746 (2004).
Eissele et al., “Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide,” Life Sci., 55(8):629-634 (1994).
Elias et al., “Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study,” Cancer 89(3):597-603 (Aug. 2000).
Eng et al., “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas,” J. Biol. Chem., 267(11):7402-7405 (1992).
Eng et al., “Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom,” J. Biol. Chem., 265(33):20259-20262 (1990).
Eppstein et al., “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor,” PNAS USA 82:3688-3692 (1985).
Eros et al., “Multiple phase emulsions as controlled drug delivery therapeutic systems,” Proc.-Conf. Colloid Chem. 193-196 (1993).
Fang et al., “The impact of baseline liver histology on virologic response to interferon α-2b±p ribavirin therapy in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572).
Felker et al., “The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface,” J. Nutritional Biochem. 4(1):630-634 (1993).
Ferenci et al, “Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977).
Fontaine et al., “Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon α,” Lancet 356(9223):41 (Jul. 2000).
Franchetti et al., “Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase,” J. Medicinal Chem. 38(19):3829-3837 (1995).
Fujii et al., “Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid,” Int'l J. Pharmaceutics 222(1):57-64 (2001).
Fujii et al., “Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP),” Int'l J. Pharmaceutics 234(1-2):121-128 (2002).
Luft et al., “Electro-osmotic valve for the controlled administration of drugs,” Med. & Biological Engineering & Computing 45-50 (Jan. 1978) (non-English with English abstract).
Gan to Kagaku Ryoho, “Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors,” Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abstract).
Gappa et al., “Juvenile laryngeal papillomatosis—a case report,” Pneumologie 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract).
Gause et al., “Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer,” J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996).
Ghiglione et al., “How glucagon-like is glucagon-like peptide-1?” Diabetologia 27:599-600 (1984).
Glue et al., “A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX(Nov. 5-9, 1999)(Abstract 571).
Goke et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells,” J. Biol. Chem., 268(26):19650-19655 (1993).
Gonzales et al., “Randomized controlled trial including an initial 4-week ‘induction’ period during one year of high-dose interferon α-2B treatment for chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975).
Gosland et al., “A phase I trial of 5-day continuous infusion cisplatin and interferon alpha,” Cancer Chemother. Pharmacol. 37(1-2):39-46 (1995).
Grant et al., “Combination therapy with interferon-α plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study,” J. Med. Virol. 61(4):439-442 (Aug. 2000).
Gutniak et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus,” N. Engl. J. Med., 326(20):1316-1322 (1992).
Hageman, “The Role of Moisture in Protein Stability,” Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988).
Heathcote et al., “Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis,” New England J. Med. 343(23):1673-1680 (2000).
Heim et al., “Intracellular signaling and antiviral effects of interferons,” Dig. Liver Dis. 32(3):257-263 (Apr. 2000).
Heinrich et al., “Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid,” Endocrinol., 115:2176-2181 (1984).
Hellstrand et al., “Histamine and cytokine therapy,” Acta Oncol. 37(4):347-353 (1998).
Hellstrand et al., “Histamine and the response to IFN-α in chronic hepatitis C,” Interferon Cytokine Res. 18(1):21-22 (Jan. 1998).
Hellstrand et al., “Histamine in immunotherapy of advanced melanoma: a pilot study,” Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994).
Hisatomi et al., “Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals,” J. Toxicol. Sci., 18(3):1-9 (1993).
Hodoshima et al., “Lipid nanoparticles for delivering antitumor drugs,” International Journal of Pharmaceutics, 146(1):81-92 (1997).
Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002).
Horton et al., “Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice” Cancer Res 59(16):4064-4068 (Aug. 1999).
Hubel et al., “A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma” Leukemia 11 Suppl 5:S47-S51 (Dec. 1997).
Iacobelli et al., “A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer,” Am. J. Clin. Oncol. 18(1):27-31 (1995).
IFNB Multiple Sclerosis Study Group, “Interferonβ-1b is effective in relapsing-remitting multiple sclerosis,” Neurology 43(4):655-667 (Apr. 1993).
Intermune® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002).
“Introduction to Antibodies”, http://www.chemicon.com/resource/ANT101/al.asp, 8 pages (retrieved May 2, 2007).
Isaacs et al., “Virus interference. I. The interferon,” Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957).
Jain et al., “Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system,” J. Microencapsulation 17(3):343-362 (2000).
Jordan et al., “Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations,” The Oncologist 12(9):1143-1150 (2007).
Kabalnov et al., “Macroemulsion type and stability of alkane-water-phospholipid systems,” Abstracts of Papers, Part 1, 210th ACS National Meeting, 0-8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only).
Kabalnov et al., “Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability,” Journal of Colloid and Interface Science 184(1):227-235 (1996).
Khalili et al., “Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C,” Am. J. Gastroenterol. 95(5):1284-1289 (May 2000).
Kildsig et al., “Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films,” J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970).
Kirkwood et al., “Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684,” J. Clin. Oncol. 14(1):7-17 (1996).
Kita et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-γ,” Drug Des. Deliv. 6(3):157-0167 (Sep. 1990).
Knepp et al, “Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor,” J. Pharm. Sci. Tech. 50(3):163-171 (1996).
Knepp et al., “Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures,” Pharma. Res. 15(7):1090-1095 (1998).
Knobler et al., “Systemic α-interferon therapy of multiple sclerosis,” Neurology 34(10):1273-1279 (Oct. 1984).
Kovacevic et al., “Treatment of chronic viral hepatitis B in using secondary membranoproliferative glomerulonephritis using recombinant α-2 interferon,” Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract).
Kracke et al., “Mx proteins in blood leukocytes for monitoring interferon β-1b therapy in patients with MS,” Neurology 54(1):193-199 (Jan. 2000).
Kronenberger et al., “Influence of interferon-α on CD82-expression in HCV-positive patients,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 976).
Krown et al., “Interferons and interferon inducers in cancer treatment,” Semin. Oncol. 13(2):207-217 (1986).
Kubes et al., “Cross-species antiviral and antiproliferative activity of human interferon-ω,” J. Interferon Res. 14:57-59 (1994).
Kunzi et al., “Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication,” J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996).
Larsson, “Stability of emulsions formed by polar lipids,” Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978).
Lee et al., “Dynamics of hepatitis C virus quasispecies turnover during interferon—A treatment,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974).
Lee, “Therapy of hepatitis C: interferon alfa-2A trials,” Hepatology 26: 89S-95S (Sep. 1997) (XP000981288).
Lopez et al., “Mammalian pancreatic preproglucagon contains three glucagon-related peptides,” Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983).
Lukaszewski et al., “Pegylated α interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection,” J. Virol. 74(11):5006-5015 (Jun. 2000).
Lund et al., “Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem,” Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982).
Lundberg, “A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol),” J. Pharm. & Pharmacol. 49(1):16-21 (1997).
Magnuson et al. “Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells,” Protein Expression & Purification 7:220-228 (1996).
Malley et al., “Chronic Toxicity And Oncogenicity Of N-Methylpyrrolidone (Nmp) In Rats And Mice By Dietary Administration,” Drug Chem Toxicol. 24(4):315-38 (Nov. 2001).
Manning et al, “Stability of protein pharmaceuticals,” Pharm. Res. 6(11):903-918 (1989).
Marincola et al., “Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer,” J. Clinical Oncol. 13(5):1110-1122 (1995) (XP009078965).
Massey, “Interaction of vitamin E with saturated phospholipid bilayers,” Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982).
McHutchison et al., “Interferon β-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C,” N. Engl. J. Med. 339(21):1485-1492 (Nov. 1998).
McHutchison et al., “Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment,” Hepatology 34(4):A333 (Oct. 1, 2001) (XP004716177) (Abstract Only).
Meier et al., “The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans,” Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006).
Merad et al., “Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-α plus IL-2 and IL-12),” J. Immunother. 23(3):369-378 (May-Jun. 2000).
Milella et al., “Neutralizing antibodies to recombinant α-interferon and response to therapy in chronic hepatitis C infection,” Liver 13(3):146-150 (Jun. 1993).
Mohler, “Primer on electrodeposited coatings,” Materials Engineering 5:38-45 (1972).
Mojsov, “Structural requirements for biological activity of glucagon-like peptide-I,” Int. J. Peptide Protein Research, 40:333-343 (1992).
Morgan, “Structure and Moisture Permeability of Film-Forming Poloyers,” Ind. Eng. Chem. 45(10):2296-2306 (1953).
Motzer et al., “Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma,” J. Clinical Oncol. 19(5):1312-1319 (2001).
Nauck et al., “Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients,” Diabet. Med., 15(11):937-945(1998).
Neumann et al., “Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy,” Science 282:103-107 (Dec. 1998).
Nieforth et al., “Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-α-2a and a polyethylene glycol-modified derivative in healthy subjects,” Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996).
Norden et al., “Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration,” Eur. J. Pharm. Sci. 13(4):393-401 (2001).
Olaso et al., “Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C,” Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract).
Ortiz et al., “A differential scanning calorimetry study of the interaction of α-tocopherol with mixtures of phospholipids,” Biochim et Biophys Acta 898(2):214-222 (1987).
Panitch, “Interferons in multiple sclerosis,” Drugs 44(6):946-962 (Dec. 1992).
Patzelt et al., “Identification and processing of proglucagon in pancreatic islets,” Nature, 282:260-266 (1979).
Peterson et al., “Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus,” ILAR Journal, 32(3):16-19 (1990).
Peterson et al., “Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa),” Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed), pp. 456-458, Smith-Gordon, London (1990).
Pimstone et al., “High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 973).
Plauth et al, “Open-label phase II study of omega interferon in previously untreated HCV infected patients,” Hepatology 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only).
Plauth et al, “Open-label study of omega interferon in previously untreated HCV-infected patients,” J. Hepatology 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only).
Pohl et al., “Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues,” J. Biol. Chem., 273(16):9778-9784 (1998).
Poynard et al., “Is an ‘a la carte’ combined interferon α 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C,” Hepatology 31(1):211-218 (Jan. 2000).
Poynard et al., “Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus,” Lancet 352(9138):1426-1432 (Oct. 1998).
“Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD,” Intarcia Therapeutics, Inc. (Sep. 22, 2010) (Press Release).
Quesada et al., “Interferons in Hematological Malignancies”, eds. Baron et al., U. Tex. 487-495 (1987).
Quintanar-Guerrero et al., “Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides,” Pharm. Res. 14(2):119-127 (1997).
Rajkumar et al., “Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma,” Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998).
Roche Pharmaceuticals, Roferon®-A (Interferon alfa-2a, recombinant), 22 pages (2003).
Roff et al., “Handbook of Common Polymers”, Cleveland Rubber Co. 72 pages (1971).
Rogers et al., “Permeability Valves,” Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957).
Roman et al., “Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL,” Transplantation 48(4):554-558 (1989).
Roth et al., “High Dose Etretinate and Interferon-alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas,” Acta Oncol. 38(5):613-617 (1999).
Roth et al., “Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity,” Endocrinol. 148(12):6054-61 (Dec. 2007).
Schepp et al., “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,” Eur. J. Pharmacol., 269(2):183-191 (1994).
Schering Corp., Intron® A for Injection, 6 pages (2001).
Schering Corp., PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003).
Schmalfub et al., “Modification of drug penetration into human skin using microemulsions,” J. Controlled Release 46(3):279-285 (1997).
Sen et al., “The interferon system: a bird's eye view of its biochemistry,” J. Biol. Chem. 267(8):5017-5020 (Mar. 1992).
Shiffman et al., “A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999) (Abstract 567).
Shima et al., “Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment,” J. Gastroenterol. Hepatol. 15(3):294-299 (Mar. 2000).
Shiratori et al., “Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy,” Ann. Int. Med. 132(7):517-524 (Apr. 2000).
Simon et al., “A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β1a,” Neurology 55(2):185-192 (Jul. 2000).
Sparks et al., “Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia,” Metabolism, 47(11):1315-1324 (1998).
Sulkowski et al., “Pegylated Interferon Alfa-2A (Pegasys™) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study,” Gastroenterology 118(4, Supp. 2) (2000) (Abstract 236).
Sulkowski et al., “Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study,” Biodrugs 16(2):105-109 (2002).
Talpaz et al., “Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia,” Blood 98(6):1708-1713 (2001).
Talsania et al., “Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice,” Endocrinology 146(9):3748-56 ( Sep. 2005).
Tanaka et al., “Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients,” Int. J. Cancer 87(5):741-749 (Sep. 2000).
Tong et al., “Prediction of response during interferon α 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison,” Hepatology 26(6):1640-01645 (Dec. 1997).
Touza Rey et al., “The clinical response to interferon-γ in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus,” Ann. Med. Int. 17(2):86-87 (Feb. 2000).
Trudeau et al., “A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer,” Cancer Chemother. Pharmacol. 35(6):496-500 (1995).
Tseng et al., “Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat,” PNAS USA, 90(5):1992-1996 (1993).
Tsung et al., “Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules,” J. Pharm. Sci. 86(5):603-7 (May 1997).
Unniappan et al., “Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY,” Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006).
Vokes et al., “A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest,” Cancer Chemother. Pharmacol. 35(4):304-312 (1995).
Vrabec, “Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing,” Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998).
Wang et al., “Preferential interaction of α-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine,” Eur. J. Biochem. 267(21):6362-6368 (2000).
Wang et al., “Ripple phases induced by α-tocopherol in saturated diacylphosphatidylcholines,” Archives of Biochem. & Biophys. 377(2):304-314 (2000).
Wang et al., “The distribution of α-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine,” Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000).
Wang et al, “Parenteral formulations of proteins and peptides: stability and stabilizers,” J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988).
Weinstock-Guttman et al., “What is new in the treatment of multiple sclerosis?” Drugs 59(3):401-410 (Mar. 2000).
Weissmann et al., “The interferon genes,” Prog. Nucleic Acid Res. Mol. Biol. 33:251-300 (1986).
Wright et al., “Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allograft recipients,” Transplantation 53(1):121-123 (Jan. 1992).
Young et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, 48(5):1026-1034 (1999).
Younossi et al., “The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with α interferons, in the treatment of chronic hepatitis C,” Semin. Liver Dis. 19(Supp. 1):95-102 (1999).
Yu et al., “Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog,” J. Pharm. Sci. 85(4):396-401 (1996).
Zeidner et al., “Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2′,3′-dideoxycytidine,” Antivir. Res. 11(3):147-0160 (Apr. 1989).
Zein, “Interferons in the management of viral hepatitis,” Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998).
Zeuzem et al., “Peginterferon Alfa-2a in Patients with Chronic Hepatitis C,” New Engl. J. Med. 343(23):1666-1672 (2000).
Zeuzem et al., “Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon α on viral turnover,” Hepatology 28(1):245-252 (Jul. 1998).
Zhang et al., “Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis,” J. Clinical Pediatrics 14(2):83-84 (1996).
Zhang et al, “A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor,” Pharm. Res. 12(10):1447-1452 (1995).
Zheng et al. “Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis,” Beijing Med. J. 13(2):80-81 (1998).
Ziesche et al., “A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis,” New Engl. J. Med. 341(17):1264-1269 (Oct. 1999).
Sanofi-Aventis U.S. LLC, Prescribing Information for ADLYXIN® (Lixisenatide) Injection, for Subcutaneous Use, rev. Jul. 2016, 31 pages.
Amylin Pharmaceuticals, Inc., Prescribing Information for BYETTA® (Exenatide) Injection, rev. Oct. 2009, 34 pages.
Astrazeneca Pharmaceuticals LP, Prescribing Information for Bydureon® (Exenatide Extended-Release for Injectable Suspension), rev. Mar. 2015, 60 pages.
Novo Nordisk A/S, Prescribing Information for Victoza® (Liraglutide [rDNA Origin] Injection), Solution for Subcutaneous Use, v. 1, Jan. 2010, 23 pages.
Glaxosmithkline LLC, Prescribing Information for Tanzeum® (Albiglutide) for Injection, for Subcutaneous Use, rev. Jun. 2014, 55 pages.
Eli Lilly & Company, Prescribing Information for Trulicity® (Dulaglutide) Injection, for Subcutaneous Use, rev. Mar. 2015, 19 pages.
Adolf, “Human interferon omega-a review,” Mult. Sclr. 1:S44-47 (1995).
Costantino et al., “Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability,” J. Pharm. Sci. 91:388-395 (2002).
Henry et al., “Comparing ITCA 650, continuous subcutaneous delivery of exenatide via Duros® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes,” oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden , 21 pages (Sep. 20-24, 2010).
Huggins et al., “Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses,” Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984).
Ishiwata et al., “Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs,” J. Vet. Med. Sci. 60(8):911-917 (1998).
Johnson et al., “How interferons fight disease,” Sci. Am. 270(5):68-75 (May 1994).
Lublin et al., “Defining the clinical course of multiple sclerosis: results of an international survey,” Neurology. 46:907-911 (1996).
Madsbad, “Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results,” Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009).
Nielsen, “Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes,” Drug Discovery Today 10(10):703-710 (May 15, 2005).
Patti et al., “Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study,” Acta. Neurol. Scand. 100:283-289 (1999).
Paty et al., “Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis,” Neurology 43:662-667 (1993).
PCT International Search Report for PCT/US2009/000916, 4 pages (Aug. 12, 2009).
“Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1,” NLV Partners Press Coverage Portfolio News (Apr. 12, 2007) (Press Release).
Quianzon et al., “Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes,” US Endocrinology 7(2):104-109 (2011).
Ratner et al., “Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial,” Diabetic Medicine 27(9):1024-1032 (Sep. 2010).
Roberts et al., “The Evolution of the Type I Interferonsl,” J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998).
Rohloff et al., “Duros Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months,” J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008).
“Sequence Listings for International Patent Application Publication No. W02009109927, WIPO Patentscope”, http://patentscope.wipo.int/search/docservicepdf_pct/id00000008776887, 1 page (last visited Nov. 14, 2012).
Shire et al., “Challenges in the Development of High Protein Concentration Formulations,” J. Pharm. Sci. 93:1390-1402 (2004).
Smith, “Peripheral Neuro-hormones as a Strategy to Treat Obesity,” oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007).
Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (dated Apr. 15, 2011).
Zhang et al., “Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers,” Current Physician 2(12):45-46 (1997).
Pratley et al., “Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors,” Rev. Diabet. Stud., 5(2):73-94 (2008).
Gonzalez, et al., “Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico,” Salud Publica Mex 55:462-468 (2013).
Ahn et al., “A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning” Journal of Medicinal Chemistry, vol. 44, No. 19, (2001): 3109-3116.
Croxatto. “Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant.” Eur J Contracept Reprod Health Care. Sep. 2000; 5 Suppl 2:21-8.
Implanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright © 2006, 2009, 2012 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
Nexplanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright © 2011 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
Probuphine_Prescribing Information. Distributed by Braeburn Pharmaceuticals, Inc. Revised May 2016.
Glumetza Brochure 2009, 13 Pages.
Erowid,“Introduction to the Federal Controlled Substance Analog Act” 2001, 4 pages.
Li et al. (“Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials” in Current Therapeutic Research, vol. 71, No. 4, Aug. 2010.
Palmeri et al., “5-Fluorouracil and recombinant β-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study,” J. Chemotherapy 2(5):327330 (Oct. 1990).
Akers, et al., “Formulation Design and Development of Parenteral Suspensions,” Journal of Parenteral Science & Technology, 41(3): 88-96 (1987).
Alonso, et al., “Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres,” Pharmaceutical Research, 10(7):945-953 (1993).
Beck, et al., “Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive,” Biology of Reproduction, 28(1): 186-195 (1983).
Bodmeier and McGinity, “Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method,” International Journal of Pharmaceutics, 43(1-2): 179-186 (Apr. 1988).
Cha and Pitt, “A one-week subdermal delivery system for I-methadone based on biodegradable microcapsules,” Journal of Controlled Release, 7: 69-78 (1988).
Cha and Pitt, “The acceleration of degradation-controlled drug delivery from polyester microspheres,” Journal of Controlled Release, 8: 259-265 (1989).
Cohen, et al., “Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres,” Pharmaceutical Research, 8(6): 713-720 (1991).
Conti, et al., “Use of polylactic acid for the preparation of microparticulate drug delivery systems,” Journal of Microencapsulation, 9(2): 153-166 (1992).
Hodgman, et al., Eds., Handbook of Chemistry and Physics, 35th Edition, 1024-1025 (1953).
Jalil and Nixon, “Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties,” Journal of Microencapsulation, 7(3): 297-325 (Jul.-Sep. 1990).
Lee and Timasheff, “The stabilization of proteins by sucrose,” J. Biological Chem., 256(14): 7193-7201 (Jul. 1981).
Li, et al., “Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method,” Journal of Controlled Release, 37: 199-214 (1995).
Maa and Hsu, “Liquid-liquid emulsification by static mixers for use in microencapsulation,” Journal of Microencapsulation, 13(4): 419-433 (Jul.-Aug. 1996).
Maulding, et al., “Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament,” Journal of Controlled Release, 3: 103-117 (1986).
Mehta, et al.,“Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide),” Journal of Controlled Release, 41: 249-257 (1996).
Sah, et al., “A novel method of preparing PLGA microcapsules utilizing methylethyl ketone,” Pharmaceutical Research, 13(3): 360-367 (1996).
Sato, et al., “Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques,” Pharmaceutical Research, 5(1): 21-30 (1988).
Szayna, et al., “Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats,” Endocrinology, 141(6): 1936-1941 (2000).
Thomasin, et al., “A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation,” Eur. J. Pharm. Biopharm., 42(1): 16-24 (1996).
Van Santbrink and Fauser, “Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens,” J. Clin. Endocrin. Metab., 82(11): 3597-3602 (1997).
Tracy et al., “Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheresin vivo and in vitro.” Biomaterials. 20(11:): 1057-1062 (1999).
Ertl et al., “Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines,” Vaccine 14(9):879-885.(1996).
Thompson et al., “Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone,” Journal of Controlled Release 43(1):9-22 (1997).

Divisions (1)

	Number	Date	Country
Parent	29566823	Jun 2016	US
Child	29604792		US

Implant placement guide

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

US Classifications

Field of Search

US

CPC

International Classifications